Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E.
Target Price
The average target price of LQDA is 50 and suggests 24% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell